PD0060: Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetcis of UCB0022 in Study Participants with Advanced Parkinson's Disease

Grants and Contracts Details

StatusActive
Effective start/end date2/22/242/22/26

Funding

  • UCB Biopharma SRL (Belgium): $10,431.00